Kangpu Biopharmaceuticals has secured IND approval from China's NMPA for KPG-818, a novel oral molecular glue modulator targeting relapsed/refractory multiple myeloma.
Kangpu Biopharmaceuticals completed a bridging clinical study of KPG-818 in healthy Chinese subjects, assessing safety, tolerability, and pharmacokinetics.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.